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Diffusely inﬁltrative astrocytic tumours are the most common neoplasms in the human brain. To localise putative tumour
suppressor loci that are involved in low-grade astrocytomas, we performed high-resolution genome-wide allelotype analysis on
17 ﬁbrillary astrocytomas. Non-random allelic losses were identiﬁed on chromosomal arms 10p (29%), 10q (29%), 14q (35%),
17p (53%), and 19q (29%), with their respective common regions of deletions delineated at 10p14-15.1, 10q25.1-qter,
14q212.2-qer, 17p11.2-pter and 19q12-13.4. These results suggest that alterations of these chromosomal regions play
important roles in the development of astrocytoma. We also allelotyped 21 de novo glioblastoma multiforme with an aim to
unveil genetic changes that are common to both types of astrocytic tumours. Non-random allelic losses were identiﬁed on 9p
(67%), 10p (62%), 10q (76%), 13q (60%), 14q (50%), and 17p (65%). Allelic losses of 10p, 10q, 14q and 17p were common
genetic alterations detectable in both ﬁbrillary astrocytomas and glioblastoma multiforme. In addition, two common regions of
deletions on chromosome 14 were mapped to 14q22.3-32.1 and 14q32.1-qter, suggesting the presence of two putative
tumour suppressor genes. In conclusion, our comprehensive allelotype analysis has unveiled several critical tumour suppressor
loci that are involved in the development of ﬁbrillary astrocytomas and glioblastoma multiforme. Although these two types of
brain tumours are believed to evolve from different genetic pathways, they do share some common genetic changes. Our
results indicate that deletions of chromosome 14q is a recurrent genetic event in the development of astrocytoma and
highlight the subchromosomal regions on this chromosome that are likely to contain putative tumour suppressor genes
involved in the oncogenesis of astrocytic tumours.
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Diffusely inﬁltrating astrocytomas are the most frequent intracra-
nial neoplasms and account for more than 60% of all primary
brain tumours. According to the World Health Organization
(WHO) classiﬁcation, diffuse astrocytomas are graded into ﬁbril-
lary astrocytoma (grade II), anaplastic astrocytoma (grade III)
and glioblastoma multiforme (GBM; grade IV) (Kleihues et al,
2000). The ﬁbrillary astrocytomas tumours have the inherent
tendency for malignant progression to higher grade, with GBM
as the most malignant phenotypic endpoint. Such glioblastomas
are termed secondary GBM, in contrast to those de novo GBM that
arise without prior known low-grade astrocytic tumours.
Molecular genetic studies on astrocytic tumours have been
performed extensively to investigate the common events involved.
In low-grade astrocytic tumours, chromosomal regions with
frequent loss have been identiﬁed on 6q, 10p, 13q, 17p and 22q
(Tsuzuki et al, 1996; Ino et al, 1999; Miyakawa et al, 2000). Muta-
tion of the TP53 gene, which is located on 17p, is the most
common genetic alteration detected in 460% tumours (von
Deimling et al, 1992a). Gains of chromosomal arms 7q and 8q
are also detected in a subset of low-grade astrocytic tumours
(Schrock et al, 1996; Nishizaki et al, 1998). Moreover, low-grade
astrocytic tumours often recur with concomitant malignant
progression to anaplastic astrocytomas or glioblastomas by acquir-
ing additional genetic changes. These alterations include 19q loss,
RB1 alteration, 10q loss, PTEN/MMAC1 mutations, loss of DCC
expression, and overexpression of PDGFR-a (Hermanson et al,
1992; von Deimling et al, 1992b; Karlbom et al, 1993; Henson et
al, 1994; Li et al, 1997; Reyes-Mugica et al, 1997; Steck et al,
1997). On the other hand, de novo GBM is characterised by a
distinct set of genetic changes that involve gene ampliﬁcation
and overexpression of EGFR and MDM2, CDKN2A deletion, 10p
and 10q loss, and RB1 alteration ( Libermann et al, 1985; Karlbom
et al, 1993; Reifenberger et al, 1993; Schmidt et al, 1994; Ueki et al,
1996).
Molecular genetic studies on low-grade astrocytic tumours have
been limited and these studies focused mostly on speciﬁc chromo-
somes and genes that are commonly affected in other tumour
types. It still remains unknown whether other autosomes are
involved in the development of astrocytomas. In this study, we
performed a comprehensive genome-wide allelotype analysis on
17 low-grade ﬁbrillary astrocytomas, using 382 microsatellite
markers that cover the 22 autosomes, with an aim to detect critical
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We also allelotyped 21 de novo GBM to identify genetic events that
are common to both types of astrocytic tumours.
MATERIALS AND METHODS
Specimens
Seventeen ﬁbrillary astrocytomas and 21 de novo GBM were
collected from hospitals in Hong Kong and China. Tumours
obtained from surgery were immediately stored at 7808C until
use. All tumours were diagnosed according to the recent WHO
criteria (Kleihues et al, 2000). Each tumour was histologically
conﬁrmed to have neoplastic cell content greater than 80%. The
corresponding peripheral blood of each patient was also obtained
as constitutional control. The mean age of patients with ﬁbrillary
astroytomas was 34+7.3 years and the male/female ratio was 1.1,
whereas patients with GBM tended to be older with a mean age
of 45.2+14.5 years and their male/female ratio was 0.9. None of
the cases were recurrences.
DNA extraction
About 20–30 pieces of 10 mm thick frozen sections of each tumour
were cut for DNA extraction. High molecular weight genomic
DNA from both blood and tumour was puriﬁed using conven-
tional proteinase K digestion and phenol-chloroform extraction.
Allelotype analysis
A high-resolution genome-wide allelotype analysis was performed
according to reported protocols (Tong et al, 2001). Brieﬂy, 382
microsatellite loci derived from 22 autosomes were examined for
allelic imbalances. The average interval of these loci is about
10 cM. The polymorphic microsatellite markers were obtained
from the ABI Prism Linkage Mapping Set V.2 (Applied Biosystems,
CA, USA) and were originally selected from the Ge ￿ne ￿thon human
linkage map. The set consists of primer pairs end-labelled with
either one of three ﬂuorochromes: FAM, HEX, or NED. PCR
was performed in a ﬁnal volume of 7.5 ml containing two primer
pairs (2.5 pmoles of each primer), 60 ng of DNA, 10 mM Tris-
HCl (pH 8.3), 50 mM KCl, 0.2 mM deoxyribonucleoside triphos-
phates, 2.5 mM MgCl2 and 0.6 unit of AmpliTaq Gold DNA poly-
merase (Applied Biosystems). To facilitate high throughput of
samples, all liquid handling and thermal cycling were carried out
in an ABI Prism 877 robotic workstation (Applied Biosystems).
PCR was started, according to manufacturer’s recommendation,
with 958C for 15 min, followed by 10 cycles composed of 948C
for 15 s, 558C for 15 s and 728C for 30 s, and another 22 cycles
composed of 898C for 15 s, 558C for 15 s and 728C for 30 s.
Ampliﬁed PCR products of multiple loci were pooled and electro-
phoresed in denaturing 5% polyacrylamide gels on an ABI Prism
377 automated DNA sequencer (Applied Biosystems). The data
collected were analysed using GeneScan Analysis software version
3.1 (Applied Biosystems). Allelic imbalance was deﬁned by calcula-
ting the allelic ratio (AR) of both normal (N) and tumour (T)
DNA, where AR was the ratio of peak height of the longer allele
(N2 or T2) to that of the shorter allele (N1 or T1), i.e.,
AR=(N2/N1)/(T2/T1). Allelic imbalance was indicated when the
ratio was greater than 1.5 or smaller than 0.5, representing loss
of longer or shorter allele respectively.
RESULTS
To localise critical tumour suppressor loci involved in the tumor-
igenesis of astrocytoma, we performed a comprehensive genome-
wide allelotype analysis on 17 ﬁbrillary astrocytomas and 21
GBM. All 22 autosomes were examined for allelic imbalances. An
average of 70% informative loci/case was detected in our series.
Allelic imbalances were seen in all 39 autosomal arms. Representa-
tive results of allelic imbalances at selected microsatellite loci are
illustrated in Figure 1.
Allelotype of ﬁbrillary astrocytomas
The frequency of allelic imbalances for individual chromosomal
arm in the low-grade astrocytoma series varied from 0% (12q,
16p, 20q and 22q) to 53% (17p) (Figure 2). The mean percentage
of allelic imbalances was 15+10%. In the present study, 25%
(mean percentage+one standard deviation) was chosen to be a
signiﬁcant percentage of allelic imbalances. This represents the
95% conﬁdence upper limit for the overall rate for random chro-
mosome loss or imbalance in tumours. Non-random allelic
imbalances above the baseline (25%) were identiﬁed on chromoso-
mal arms 10p (29%), 10q (29%), 14q (35%), 17p (53%), and 19q
(29%). Comparative genomic hybridisation (CGH) analysis was
also performed on three tumours, in which sufﬁcient DNA was
available. These tumours were conﬁrmed to have deletion regions
identiﬁed by allelotyping (data not shown).
We have also delineated the common regions of deletion
(CRDs) on chromosomes that are frequently lost in ﬁbrillary astro-
cytomas. Two CRDs were mapped on chromosome 10, one was
located to a region of 5.2 cM on 10p14-15.1 (between D10S591
and D10S189) and the other was mapped to a region of 42.4 cM
between 10q25.1 (marker D10S597) and the telomere of long
arm. The LOH frequency at this region was 29% (ﬁve of 17 infor-
mative cases). The CRD on chromosome 14q was localized to a
region of 85 cM between 14q21.2 (D14S288) and the 14q telomere
(Figure 4). The LOH frequency at this region was 35% (six of 17
informative cases). On chromosome 17, one CRD was deﬁned
within 17p11.2 (D17S799) and the 17p telomere, with a LOH
frequency of 53% (nine of 17 informative cases). Another CRD
of 51.2 cM was delineated on chromosome 19q12-13.4, between
markers D19S414 and D19S210. The LOH frequency at this region
was 29% (ﬁve of 17 informative cases). In addition, chromosomal
arms with frequencies of allelic imbalances higher than the mean
percentage of LOH were identiﬁed on 2q (24%), 3p (18%), 6p
(18%), 6q (24%), 7q (18%), 8q (18%), 10p (24%), 11p (18%),
13q (18%), 15q (18%) and 21q (18%).
Allelotype of GBM
The frequency of allelic imbalances for individual chromosomal
arm in the GBM series varied from 10% (8q) to 76% (10q) (Figure
3). The mean percentage of allelic imbalance was 32+15.9%, with
47.9% (mean percentage+one standard deviation) chosen to be a
signiﬁcant percentage of allelic imbalances. Non-random allelic
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Figure 1 Representative results of allelotype analysis. Allelic patterns of
ﬁve polymorphic loci on chromosomal arm 14q examined in a ﬁbrillary
astrocytoma (case 21) are shown. Allelic loss is indicated by arrow.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 218–224imbalances were detected on chromosomes 9p (67%), 10p (62%),
10q (76%), 13q (60%), 14q (50%) and 17p (65%).
The CRD of 11.1 cM on chromosome 9 was mapped to 9p21-23,
ﬂanked by markers D9S286 and D9S285. The LOH frequency at
this region was 62%. Three CDRs were observed on chromosome
10, at 10p15-pter (16.5 cM between D10S189 and D10S249),
10q23.3-25.1 (9.9 cM ﬂanked by D10S185 and D10S597), and
10q25.3-26.3 (30.6 cM between D10S1693 and D10S1651). The
LOH frequencies at these deletion regions were 58% (11 of 19
informative cases), 77% (13 out of 17) and 58% (11 out of 19),
respectively. On chromosome 13, the CDR lied in a region of
50.7 cM, between markers D13S217 and D13S170. The frequency
of LOH at this 13q13.2-31 deletion region was 50% (10 out of
20). Two CRDs were located on chromosome 14: one was mapped
to 14q22.3-32.1 (48.9 cM between D14S276 and D14S280) and the
other was localised between 14q32.1 and 14q telomere (28.3 cM
between D14S280 and pter), with LOH frequency of 50% (10 out
of 20) and 44% (eight out of 18), respectively (Figure 4). Another
CRD was observed between 17p12 (D17S1852) and 17p telomere
(23 cM). This deletion region was detected in 60% (12 out of 20)
of informative cases.
CGH analysis was performed on nine GBM and conﬁrmed the
deletion regions identiﬁed by allelotyping. Chromosomal regions
that show gain of genetic material had been analysed by array-
based CGH, in which 58 oncogenes/amplicons were investigated,
and were reported elsewhere (Hui et al, 2001).
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Figure 2 Summary of allelic imbalances detected in 17 ﬁbrillary astrocytoma. Case number is indicated on top and fractional allelic loss (FAL) value is
shown at bottom. Frequency of LOH is indicated on right, with bold number representing non-random allelic imbalance frequency above the baseline level
(25%). Filled box represents allelic imbalance detected in speciﬁed chromosomal arm and open box indicate chromosomal arm with no detectable allelic
imbalance. X, not done.
Chromosome 14q loss in astrocytic tumours
JH uet al
220
British Journal of Cancer (2002) 87(2), 218–224 ã 2002 Cancer Research UKFractional allelic loss
The fractional allelic loss (FAL) for each tumour was also deter-
mined (Figures 2 and 3). FAL is deﬁned as the fraction of the
total number of informative chromosomal arms that displays allelic
loss (Vogelstein et al, 1989). In the present study, the mean FAL
values for ﬁbrillary astrocytomas and GBM were 0.15 (range, 0–
0.67) and 0.33 (range, 0–0.95), respectively. This result indicates
that additional genetic alterations were accumulated in GBM.
There was no association between the FAL values and the age/sex
of the patients. By using Mann–Whitney U-test, high FAL value
was found to be signiﬁcantly associated with chromosomes 10q
(P=0.05), 14q (P=0.01) and 19q (P=0.01) in ﬁbrillary astrocytomas,
and 9p (P50.01), 14q (P=0.02) and 17p (P50.01) in GBM. More-
over, microsatellite instability was rarely found in our series.
DISCUSSION
In this study, we performed a comprehensive genome-wide allelo-
type analysis on a series of 17 low-grade astrocytomas and 21 de
novo GBM with an aim to localise putative tumour suppressor loci
involved in astrocytic tumours. Non-random chromosome losses
were identiﬁed on 10p, 10q, 14q, 17p and 19q in ﬁbrillary astrocy-
tomas, and on 9p, 10p, 10q, 13q, 14q and 17p in GBM (Table 1).
These results strongly indicate that alterations of these chromo-
somes play critical roles in the genesis of astrocytoma.
Mutation of the TP53 gene and/or allelic loss of 17p is the most
prominent genetic alteration detected in 460% of ﬁbrillary astro-
cytomas (von Deimling et al, 1992a). Study on malignant
progression of low-grade astrocytomas to high-grade tumours
revealed that the frequencies of TP53 mutation were comparable
in both groups of tumours, suggesting that TP53 mutation is an
early event in the evolution of diffuse astrocytoma (Watanabe et
al, 1997). Our allelotype analysis identiﬁes a CRD between
17p11.2 and 17p telomere, which encompasses the TP53 locus, as
the major genetic alteration in the low-grade astrocytomas.
In the present study, allelic loss of 14q is the second most
common genetic alteration detected in ﬁbrillary astrocytomas.
Since chromosome 14 has never been a target under investigation
for genetic changes in low-grade astrocytomas, we therefore
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Figure 3 Summary of allelic imbalances detected in 21 GBM. Case number is indicated on top and fractional allelic loss (FAL) value is shown at bottom.
Frequency of LOH is indicated on right, with bold number representing non-random allelic imbalance frequency above the baseline level (47.9%). Filled box
represents allelic imbalance detected in speciﬁed chromosomal arm and open box indicate chromosomal arm with no detectable allelic imbalance. X, not
done.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 218–224reviewed genetic results from three genome-wide studies covering
a total of 40 ﬁbrillary astrocytomas (Schrock et al, 1996; Sallinen
et al, 1997; von Deimling et al, 2000). Sallinen et al (1997)
detected chromosome loss of 14q in 18% tumours by CGH,
whereas Schrock et al (1996) (with CGH) and von Deimling et
al (2000) (with allelotype analysis) detected no alteration in chro-
mosome 14q. It should be noted that only three polymorphic
markers on chromosome 14q were examined in the latter allelo-
typing study. Our allelotype analysis investigated 14 polymorphic
loci on the long arm of chromosome 14 and detected 35% of
tumours with 14q loss. Moreover, we were able to delineate a
CRD between 14q21.2 and 14q telomere. Although low-grade
astrocytomas and de novo GBM are regarded as two groups of
brain tumours with distinct genetic changes, we did observe 14q
loss in 50% of GBM in our series. In addition, two CRDs were
localised on chromosome 14 in GBM, one mapped to 14q22.3-
32.1 and the other deﬁned within 14q32.1 and 14q telomere
(Figure 4). The presence of two CRDs suggests that there are
two tumour suppressor genes located on chromosome 14q. It
seems that chromosome 14q loss is a common event for both
low-grade astrocytomas and de novo GBM. Further study is needed
to reﬁne the deletion regions on chromosome 14q for positional
cloning of the tumour suppressor genes involved in astrocytomas.
Frequent deletion of 14q has also been detected in a variety of
tumours such as meningioma, neuroblastoma, breast and ovarian
cancer (Suzuki et al, 1989; Bandera et al, 1997; Tse et al, 1997;
O’Connell et al, 1999). Deletion mapping has identiﬁed at least
three tumour suppressor loci on 14q that are important for cancer
development. These regions are mapped to 14q11-13, 14q22-24
and 14q32 (Bandera et al, 1997; Tse et al, 1997; O’Connell et al,
1999). The latter two regions overlap with the deletion regions
delineated in this study. Thus, deletion at 14q is a common feature
in different tumour types including astrocytic tumours. A candi-
date tumour suppressor gene, MLH3, has been identiﬁed on
14q24.3. MLH3 is a mismatch-repair gene and mutation of this
gene is associated with microsatellite instability in colorectal
tumours (Lipkin et al, 2001). Other mismatch-repair genes such
as MLH1 and MSH2 have been found to be mutated in a subset
of malignant gliomas (Leung et al, 1998). Whether genetic altera-
tion of MLH3 plays a role in astrocytoma formation remains to be
determined.
Allelic loss of chromosome 19q was detected in 29% and 33%
of ﬁbrillary astrocytomas and GBM, respectively, in our allelotype
analysis. These results are consistent with previous allelotyping
study and suggest the presence of a tumour suppressor gene on
19q. Chromosome 19q loss is the only known genetic alteration
that is shared by the three major glioma subtypes, astrocytomas,
oligodendrogliomas and oligoastrocytomas (von Deimling et al,
1992b). The deletion breakpoint on 19q has been mapped to
the segment 19q13.3. Recent ﬁner deletion mapping have identi-
ﬁed two overlapping regions, ﬂanked by markers D19S241 and
STD, with high frequency of allelic loss (Rosenberg et al, 1996;
Smith et al, 2000a). A partial transcript map has been constructed
for this deletion region (Smith et al, 2000b) and it remains to be
determined if any of these genes is the tumour suppressor for
gliomas.
Deletions of chromosome 10 are among the most frequent
genetic alterations in astrocytomas, particularly in the high-grade
variants. Several deletion regions have been identiﬁed on both arms
of chromosome 10 and these regions have been mapped to 10p15,
10p14 and 10q25 (Rasheed et al, 1995; Voesten et al, 1997; Ichi-
mura et al, 1998; Kon et al, 1998). The presence of tumour
suppressor genes on these deletion regions is supported by chro-
mosome transfer studies (Pershouse et al, 1993; Kon et al, 1998).
Two putative tumour suppressor genes, namely PTEN/MMAC1
and DMBT1, have been identiﬁed on chromosome 10q23.3 and
10q25, respectively (Li et al, 1997; Mollenhauer et al, 1997; Steck
et al, 1997). In this study, we detected chromosome 10 loss in
seven (41%) ﬁbrillary astrocytomas and 18 (86%) GBM, support-
ing the notion that chromosome 10 plays an important role in
astrocytoma formation. Recent study also suggests that low-grade
astrocytomas with chromosome 10 loss are likely to undergo
malignant progression (Ichimura et al, 1998). Whether the ﬁbril-
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Figure 4 Delineation of common region of deletion on chromosomal arm 14q in astrocytic tumors. Fourteen polymorphic loci, with their respective
genetic intervals in centiMorgan (cM), were examined for allelic loss. Two common regions of deletion (thick bars) are identiﬁed: 14q22.3-32.1 and
14q32.1-qter. Filled circle represents loss of heterozygosity and open circle denotes retention of heterozygosity. Dash line indicates homozygosity. The can-
didate tumour suppressor gene, MLH3, is located between markers D14S258 and D14S74 on the genetic map.
Table 1 Summary of critical deletion regions identiﬁed in 38 astrocytic
tumours
Frequency of LOH (%)
a
Chromosomal Fibrillary Deletion
arms astrocytoma GBM regions
9p 6 62 9p21-23
10p 29 58 10p15-pter
10q 29 77/58 10q23.3-24.1/10q25.3-26.3
13q 18 60 13q13.2-31
14q 35 50/40 14q22.3-32.1/14q32.1-qter
17q 53 60 17q11.2-pter
19q 29 33 19q12-13.4
aBold number is LOH frequency considered to be signiﬁcant.
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further follow-up evaluation.
In the GBM series, we detected non-random chromosome losses
on 9p13.3-21.3 (58%), 10p15-pter (77%), 10q23.3-25.1 (58%),
13q13.2-31 (50%), 14q22.3-32.1 (50%) and 17p12-pter (60%).
We compared our results with the published allelotyping data
(von Deimling et al, 2000) and found that the data, except for
LOH 17q, from both studies were largely comparable. The
frequency of 17q loss in de novo GBM is the highest frequency
reported to date and this is consistent with another series of
GBM that we examined in previous study (Cheng et al, 1999).
The putative tumour suppressor genes on some of these chromo-
somes have been identiﬁed and their associated genetic pathways
are elucidated. For instance, CDKN2A (on 9p21) and RB1 (on
13q14.2) are involved in the cell cycle control; p14
ARF (on 9p21)
negatively regulates TP53 (on 17p13.1) function; and PTEN/
MMAC1 (on 10q23.3) is involved in the PI3K/AKT pathway. These
pathways are believed to play important roles in the development
and progression of astrocytoma. Recently, Pieper’s group using a
functional approach demonstrated that normal astrocytes could
be transformed to astrocytoma by interfering with the telomerase,
RAS, CDKN2A/RB1 and TP53 pathways (Sonoda et al, 2001a).
They further showed that additional disturbance of the PI3K/
AKT pathway elicited a glioblastoma phenotype in the in vitro
transformed astrocytoma (Sonoda et al, 2001b). Thus, conversion
of normal astrocytes to glioblastoma requires disruptions of at least
ﬁve genetic pathways. The roles of other tumour suppressor loci on
10p and 14q in astrocytoma formation remain to be elucidated.
In conclusion, our comprehensive allelotype analysis have
unveiled several critical tumour suppressor loci that are involved
in the development of ﬁbrillary astrocytomas and GBM. Although
these two types of brain tumours are believed to evolve from
different genetic pathways, they do share some common genetic
changes. Our results indicate that deletions of chromosome 14q
is a recurrent genetic event in the development of astrocytoma
and highlight the subchromosomal regions on this chromosome
that are likely to contain putative tumour suppressor genes
involved in the oncogenesis of astrocytic tumours.
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